Seroatlas · Human Serome Atlas

LHFPL2

LHFPL tetraspan subfamily member 2 protein

Also known as: KIAA0206, LHPL2_HUMAN

Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene

Protein identityUniProt · HPA

UniProt accession: Q6ZUX7
Gene: LHFPL2
Ensembl: ENSG00000145685
Chromosome: 5
Canonical length: 228 aa
Protein class: Predicted membrane proteins
Subcellular location: Nuclear bodies,Vesicles,Plasma membrane

OverviewNCBI Gene

This gene is a member of the lipoma HMGIC fusion partner (LHFP) gene family, which is a subset of the superfamily of tetraspan transmembrane protein encoding genes. Mutations in one LHFP-like gene result in deafness in humans and mice, and a second LHFP-like gene is fused to a high-mobility group gene in a translocation-associated lipoma. Alternatively spliced transcript variants have been found, but their biological validity has not been determined. [provided by RefSeq, Jul 2008]

Canonical amino-acid sequenceUniProt

228 residues, UniProt reviewed canonical sequence.

>Q6ZUX7|LHFPL2
     1  MCHVIVTCRS MLWTLLSIVV AFAELIAFMS ADWLIGKARS RGGVEPAGPG GGSPEPYHPT
    61  LGIYARCIRN PGVQHFQRDT LCGPYAESFG EIASGFWQAT AIFLAVGIFI LCMVALVSVF
   121  TMCVQSIMKK SIFNVCGLLQ GIAGLFLILG LILYPAGWGC QKAIDYCGHY ASAYKPGDCS
   181  LGWAFYTAIG GTVLTFICAV FSAQAEIATS SDKVQEEIEE GKNLICLL

LocalizationUniProt · AlphaFold · HPA

Whether an antibody against LHFPL2 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.

Antibody reachability: Cell surface
Secreted: No
Transmembrane segments: 4
Mean surface accessibility (rSASA): 0.31
Highest tissue expression: 34 nTPM

Expression across tissuesHPA

Tissue

urinary bladder: 34 nTPM
seminal vesicle: 23 nTPM
duodenum: 22 nTPM
gallbladder: 21 nTPM
ovary: 21 nTPM
smooth muscle: 21 nTPM

Single-cell type

microglia: 837 nCPM
lacrimal acinar cells: 246 nCPM
epicardial cells: 241 nCPM
schwann cells: 231 nCPM
foveolar cells: 191 nCPM
endometrial stromal cells: 184 nCPM

Immune cell

basophil: 8 nTPM
plasmacytoid DC: 6.3 nTPM
eosinophil: 4 nTPM
classical monocyte: 3.9 nTPM
intermediate monocyte: 1.4 nTPM
total PBMC: 1.3 nTPM

Brain region

thalamus: 33 nTPM
white matter: 32 nTPM
medulla oblongata: 29 nTPM
choroid plexus: 25 nTPM
spinal cord: 24 nTPM
pons: 23 nTPM

Genetic constraint and essentialitygnomAD · DepMap

Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.

gnomAD LOEUF (loss-of-function intolerance): 1.04
gnomAD pLI: 0.06
gnomAD missense Z: 1.05
DepMap mean gene effect: 0.07
DepMap dependency class: none

Cancer expressionTCGA

Across TCGA tumor cohorts, this protein is over-expressed in roughly 4% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).

OntologyGO

Biological processes

Cellular components

Protein domainsUniProt · Pfam · InterPro

KeywordsUniProt

Antibody and autoantibody relevanceSeroatlas analysis

Seroatlas reads LHFPL2 as an antibody target. Whether an autoantibody or antibody against LHFPL2 could matter depends on whether native LHFPL2 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.

LHFPL2 is annotated at the cell surface, where native LHFPL2 is exposed to circulating antibodies and is a prime autoantibody target that could block, deplete, or overstimulate it.

Annotation status

The present source text does not explicitly label LHFPL2 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.

Loading the interactive Seroatlas protein explorer...